Monocyte Syk Phosphorylation as a Candidate Biomarker of Vasoplegic Shock After Cardiac Surgery with Cardiopulmonary Bypass: A Proof-of-Concept Observational Study

Heart surgery is a monumental feat of modern medicine, yet it carries a hidden cost that begins the moment the heart is stopped and restarted. During the procedure, a machine known as a cardiopulmonary bypass takes over the work of the heart and lungs, circulating blood through the body while surgeons operate. This artificial circulation, while life-saving, acts as a massive trigger for the immune system. The blood, suddenly exposed to the plastic and metal of the machine, wakes up the body's defense cells. These cells, specifically the monocytes and neutrophils that patrol the bloodstream, become activated and release a storm of chemical signals. In some patients, this reaction goes too far, leading to a dangerous condition called vasoplegic shock. In this state, the blood vessels lose their ability to tighten, causing blood pressure to plummet despite the heart pumping normally. Doctors must then rely on powerful drugs to squeeze the vessels back into shape, a situation that often leads to longer hospital stays and a higher risk of organ failure. For years, researchers have searched for a way to predict who will fall into this trap before it happens, hoping to identify the patients who need extra care the moment they wake up from surgery.

A team of researchers at a hospital in Paris set out to find such a predictor by looking inside the very cells that drive this inflammatory storm. They focused on three specific proteins that act as switches within immune cells, deciding whether to turn the inflammatory response up or down. One of these proteins, known as Syk, acts as an accelerator; when it is chemically modified in a specific way, it tells the cell to release its inflammatory weapons. The team wanted to see if measuring the state of this switch in the blood cells of patients could forecast who would need those life-saving blood-pressure drugs the day after surgery. They recruited twenty-three patients scheduled for heart surgery with the bypass machine. Before the surgery began, they took a blood sample to establish a baseline, measuring how active these protein switches were in a resting state. They took another sample immediately after the bypass machine was turned off, and then again on the first, third, and seventh days following the operation. By comparing the activity of the proteins before and after the machine, they hoped to spot a pattern that distinguished the patients who would remain stable from those who would crash.

The results revealed a surprising complexity in how the body reacts to surgery. Immediately after the bypass machine was stopped, the researchers found that the immune cells were not in a state of hyper-activity as one might expect. Instead, the chemical signals that usually tell these cells to attack were actually dimmed. This suggested that the body might be entering a temporary state of immune suppression right after the trauma of surgery, a phase that could leave patients vulnerable to infection later on. However, the study did not find a simple link between the raw amount of protein activity after surgery and the need for blood-pressure drugs. The levels varied too much from person to person to be useful on their own. The breakthrough came when the researchers looked at the change in activity relative to each patient's starting point. They discovered that in the patients who required norepinephrine, a drug to raise blood pressure, on the first day after surgery, the activity of the Syk protein in their monocytes had not dropped as much as it had in the patients who remained stable. In other words, the cells of the patients who got sick still held onto a higher level of this "accelerator" signal immediately after the surgery.

When the team analyzed this difference, they found a specific threshold that separated the two groups. If the drop in Syk activity was small, the patient was highly likely to need blood-pressure support the next day. In their small group of twenty-three patients, this measure correctly identified every single person who would need the drug, while correctly ruling out most of those who would not. The patients whose cells showed this higher residual activity also had more signs of stress in their blood, such as higher levels of waste products and lower platelet counts, and they stayed in the intensive care unit longer. The researchers noted that this signal was not simply a reflection of how long the surgery lasted or how sick the patient was before the operation; it appeared to be a unique fingerprint of how the immune system responded to the bypass machine itself.

Despite these promising findings, the authors are careful to frame this as an early step rather than a final solution. The study was small, involving only four patients who actually needed the blood-pressure drugs, which means the statistical certainty is limited. The threshold they identified was calculated using the same group of people they tested it on, a method that often makes results look better than they truly are. Furthermore, the link they found did not hold up as strongly when they applied strict mathematical corrections for the number of different tests they ran. The researchers conclude that while the phosphorylation status of the Syk protein in monocytes is a compelling candidate for a new biomarker, it is not yet ready for daily clinical use. They suggest that this approach, which looks at the internal state of the immune cells rather than just the chemicals they release, offers a more direct window into the body's reaction to surgery. The next step, they argue, is to test this idea in a much larger group of patients to see if it can reliably guide doctors in deciding who needs early rehabilitation and who requires intensive monitoring. Until then, the story of the immune switch remains a fascinating clue, pointing toward a future where we might understand the body's recovery from heart surgery with greater precision.